European Pharmaceutical Review
SEPTEMBER 29, 2023
Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).
European Pharmaceutical Review
DECEMBER 12, 2023
He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 1, 2022
AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. AMR is already the third leading cause of death worldwide, causing around 1.27
pharmaphorum
JUNE 8, 2021
At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%
Hospital Pharmacy Europe
AUGUST 17, 2023
In the last decade, immunotherapies that treat cancers using the patient’s immune system to recognise, attack and kill malignant cells have reached the market. Cancer is one of the leading causes of death globally, and improving therapeutic strategies in haematology and oncology remains a priority in healthcare.
Roots Analysis
OCTOBER 24, 2023
Hence, they are commonly used in the treatment of cancer, as part of the chemotherapy regime. Besides cancer, they are also increasingly being used for other medical conditions such as rheumatoid arthritis, multiple sclerosis and other auto immune disorders. They can also inhibit or prevent the function of cells.
European Pharmaceutical Review
APRIL 10, 2024
While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.
Expert insights. Personalized for you.
109 
Let's personalize your content